This technology stands out for its fine-tuned control over chemokine delivery kinetics, enabling clinicians to customize release profiles to match tissue healing timelines. The broad array of dosage forms supports different therapeutic strategies, from intra-articular injections to targeted systemic distribution. Unlike conventional bolus therapies, these particles establish chemokine gradients that harness endogenous MSC homing, reducing reliance on exogenous cell implantation. Their modular design and non-toxic degradation products offer a flexible platform for precision regenerative medicine in chronic inflammatory disorders.
Description
The alginate-based microparticles are engineered carriers of chemokines such as PDGF, CXCL12, and CCL22 for recruiting multipotent stem cells to sites of injury or inflammation. By varying alginate concentration from 1% to 4%, they achieve predictable release profiles—trimodal at 1% and 2%, bimodal at 1.5%, exponential at 3%, and linear at 4%—over periods up to 40 days. These biocompatible microparticles degrade in vitro without MSC cytotoxicity and have been shown in mouse and osteochondral models to promote stem cell migration into cartilage defects. They can be formulated as gels, creams, injectables, liposomal suspensions, or transdermal patches and administered locally or systemically with targeting ligands for personalized treatment of autoimmune conditions and osteoarthritis.
Applications
Osteoarthritis injectable therapy
Autoimmune disease targeted delivery
Cartilage regeneration scaffolds
Wound healing chemokine gels
Transdermal chemokine patches
Advantages
Tailored chemokine release kinetics (trimodal, bimodal, exponential, or linear) sustained up to 40 days
Predictable delivery profiles by adjusting alginate concentration
Efficient recruitment of endogenous MSCs to sites of injury or inflammation
Biodegradable, non-cytotoxic microparticles ensuring biocompatibility
Versatile formulations and administration routes (injectables, gels, creams, liposomes, transdermal, oral)
Local and targeted systemic delivery for osteoarthritis and autoimmune diseases
Personalized therapy leveraging the patient’s own stem cells for tissue repair and regeneration
IP Status
https://patents.google.com/patent/US20210386825A1
